# Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)

> **NCT01476085** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 1 (actual)

## Conditions studied

- Cancer

## Interventions

- **RADIATION:** ML10

## Key facts

- **NCT ID:** NCT01476085
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study terminated as ongoing analysis suggested objectives not practical to achieve with study as implemented
- **Last updated:** 2013-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01476085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01476085, "Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01476085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*